ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
Orum Therapeutics Logo

Orum Therapeutics

We are pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, and thereby improve the therapeutic window of drugs. Our goal is to bring life-changing therapies to patients by combining the power of the emerging field of protein degraders with the precision of antibodies to generate a broad portfolio of highly differentiated product candidates. A portfolio of highly differentiated products combining the power of protein degraders with the precision of antibodies.

Quick overview

Kazan, Russia

Founded in 2016

11-50 Employees

Additional information

Working industry

Biotechnology

Type of company

-

Ownership structure

Privately Held

Locations

2 Locations

Number of products

3 Products

Number of services

3 Services

Specialised areas

Therapeutics, Oncology, Biotechnology, TPD, Targeted protein degradation, Health Care

Products & services of Orum Therapeutics

Orum Therapeutics offers a wide range of products and services

Product: Orum Therapeutics Appoints Greg Dwyer as Head of Business Development and Tina Karunaratne as Head of Clinical Operations — Orum Therapeutics

Service

Orum Therapeutics Appoints Greg Dwyer as Head of Business Development and Tina Karunaratne as Head of Clinical Operations — Orum Therapeutics

Go to product >

Product: Orum Therapeutics Announces $30 Million Series B Financing — Orum Therapeutics

Product

Orum Therapeutics Announces $30 Million Series B Financing — Orum Therapeutics

Go to product >

Product: Orum Therapeutics Unveils New Program at AACR 2023, Highlighting Cbl-b Inhibitor-PD-1 Conjugate, and Presents New Data Supporting Clinical Development of Two GSPT1 Programs — Orum Therapeutics

Service

Orum Therapeutics Unveils New Program at AACR 2023, Highlighting Cbl-b Inhibitor-PD-1 Conjugate, and Presents New Data Supporting Clinical Development of Two GSPT1 Programs — Orum Therapeutics

Go to product >

Product: Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors — Orum Therapeutics

Service

Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors — Orum Therapeutics

Go to product >

Product: Orum Therapeutics Raises $8 Million Series A Financing to Advance Cell-Penetrating Antibody Technology for Novel Cancer Therapeutics — Orum Therapeutics

Product

Orum Therapeutics Raises $8 Million Series A Financing to Advance Cell-Penetrating Antibody Technology for Novel Cancer Therapeutics — Orum Therapeutics

Go to product >

Product: UBS Virtual Biotechnology Private Company Symposium, New York, 21-22 Sep 2022 — Orum Therapeutics

Product

UBS Virtual Biotechnology Private Company Symposium, New York, 21-22 Sep 2022 — Orum Therapeutics

Go to product >

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

Russia


Overall risk estimation:

Medium


ESG country scores

The ESG Data of countries are based on public sources

Environment

B

Grade (A-E)

View details

Social

C

Grade (A-E)

View details

Governance

E

Grade (A-E)

View details

Use Cases of Orum Therapeutics

Get insights into the use cases of Orum Therapeutics

UseCase: Project Manager (PM) - Daejeon, Korea — Orum Therapeutics

Use case

Project Manager (PM) - Daejeon, Korea — Orum Therapeutics

JOB TITLE Project Manager (PM)    Location Daejeon, Korea Company Overview Orum Therapeutics is a global biotech pioneering the precise delivery of targeted protein degraders and other next generation ADC payloads to improve the treatment of cancer. The compa

UseCase: Project Leader - Translational Pharmacology — Orum Therapeutics

Use case

Project Leader - Translational Pharmacology — Orum Therapeutics

JOB TITLE Project Leader – Translational Pharmacology Location:   Cambridge, MA Company Overview Orum Therapeutics is a global biotech pioneering the precise delivery of targeted protein degraders and other next generation ADC payloads to improve the treatment of cancer.

Headquarter of Orum Therapeutics

Orum Therapeutics operates in 2 countries around the world

City: Kazan

State: Tatarstan

Country: Russia

Locations of Orum Therapeutics

Get an overview of the locations of Orum Therapeutics

Location

Country

State

City

Headquarter

Russia

Tatarstan

Kazan

North America

United States

Massachusetts

Cambridge

Frequently asked questions (FAQ) about Orum Therapeutics

Some frequent questions that have been asked about Orum Therapeutics

The company headquarter of Orum Therapeutics is located in Kazan, Tatarstan, Russia. Orum Therapeutics has subsidiaries in United States

As of the latest available information Orum Therapeutics has around 11-50 employees worldwide.

Orum Therapeutics was founded in 2016

The company Orum Therapeutics has it's main focus in the industries of Biotechnology

Competitors of Orum Therapeutics

Check out some interesting alternative companies to Orum Therapeutics

16250 - 1st TPD Europe 2020's Logo

16250 - 1st TPD Europe 2020

London, United Kingdom

1-10 Employees

-

As the industry consolidates pipelines and heads out of a turbulent 2023 market, the targeted protein degradation engine has shown no signs of slowing. Our blossoming community of degrader experts are inspiring each other to develop medicines to address patients’ unmet medical needs. Dedicated to Progressing the Field with Groundbreaking Research.

Proteovant Therapeutics's Logo

Proteovant Therapeutics

Philadelphia, United States

11-50 Employees

2021

The power of protein degradation is now being realized. This innate cellular process is responsible for maintaining protein homeostasis, and we are now exploiting it to break down the proteins that cause disease. The protein degradation opportunity is immense and reaches across a broad range of disease areas in which new and enhanced treatments are needed. Development of the best, most effective medicines for patients requires extensive biology insight, medicinal chemistry experience, drug discovery expertise and cutting-edge computational tools such as artificial intelligence and machine learning. Proteovant is leveraging targeted protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases.

Scorpion Therapeutics's Logo

Scorpion Therapeutics

Boston, United States

11-50 Employees

2020

We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy. Delivering superior precision medicines via the integration of advanced technologies and scientific excellence. Our world-class team is comprised of experts in cancer biology, medicinal chemistry, next-generation chemical proteomics, computational chemistry and molecular biophysics, machine learning, and drug development. Our fully integrated discovery platform is built upon the most advanced technologies available for drug discovery, small molecule design, and target identification that we believe will enable us to rapidly create highly selective small molecule compounds against an unprecedented spectrum of targets. Aiming to deliver a fast, precise and lethal strike at cancer’s unique drivers. Together, they have architected a new and innovative approach to target and drug discovery.

Avilar Therapeutics's Logo

Avilar Therapeutics

Waltham, United States

11-50 Employees

-

We are developing ATACs (ASGPR Targeting Chimeras), a novel class of degrader designed to harness a natural endogenous process for protein degradation. We are building an organization that is taking science to new limits and has respect for everyone. We have built a bespoke, integrated, and modular drug discovery platform to enable the design and assembly of ATACs targeting a wide array of extracellular proteins.

Camino Pharma's Logo

Camino Pharma

San Diego, United States

1-10 Employees

2014

Our goal is to discover and develop novel, first-in-class medicines for patients suffering from 1) the most aggressive forms of cancer with currently limited treatment options, and 2) psychiatric disorders that are poorly addressed by current medications, including addiction and treatment resistant depression. Our innovative technology platform allows for exploiting inadequately served targets that require a highly adaptive and specialized approach to drug discovery.

Scopus BioPharma's Logo

Scopus BioPharma

New York, United States

1-10 Employees

2018

We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we are capitalizing on groundbreaking scientific and medical discoveries at some of the world’s foremost research and academic institutions.